• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis
2023     National Institute for Health and Care Excellence (NICE) Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy. NICE technology appraisal guidance 913
2023     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical stimulation of the trigeminal nerve for ADHD. NICE interventional procedures guidance 748
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cold plasma in wound therapy (2nd addendum to Commission E21-03)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Effectiveness and safety of bioelectrical stimulation techniques in fibromyalgia: systematic review]
2023     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 914
2023     National Institute for Health and Care Excellence (NICE) Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. NICE interventional procedures guidance 747
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Valoctocogen roxaparvovec (haemophilia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies]
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2023     National Institute for Health and Care Excellence (NICE) Pegunigalsidase alfa for treating Fabry disease. NICE technology appraisal guidance 915
2023     NIHR Health Technology Assessment programme Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: the UCON randomised controlled trial and mechanism of action study
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maralixibat (cholestatic pruritis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V]
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating active psoriatic arthritis. NICE technology appraisal guidance 916
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fenfluramine (Lennox-Gastaut syndrome, add-on therapy, = 2 years) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Evaluation of the lung cancer screening program]
2023     National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 917
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (generalized myasthenia gravis) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2023     Agency for Care Effectiveness (ACE) Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating axial spondyloarthritis. NICE technology appraisal guidance 918
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olopatadine/mometasone furoate (allergic rhinitis) - Addendum to Commission A22-125]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V]
2023     Penn Medicine Center for Evidence-based Practice (CEP) Medication review and reconciliation in the outpatient setting
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for treating migraine. NICE technology appraisal guidance 919
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V - Third addendum to Commission H20-02]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     NIHR Health Technology Assessment programme Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit–risk assessment: the BRAINS study including expert workshop
2023     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 920
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     NIHR Health Technology Assessment programme Pragmatic randomised controlled trial of guided self-help versus individual cognitive behavioural therapy with a trauma focus for post-traumatic stress disorder (RAPID)
2023     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating polycythaemia vera. NICE technology appraisal guidance 921
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) - benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Current scientific knowledge on myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Penn Medicine Center for Evidence-based Practice (CEP) Antibiotic-laden bone cement
2023     National Institute for Health and Care Excellence (NICE) Daridorexant for treating long-term insomnia. NICE technology appraisal guidance 922
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for defibrillators and pacemakers]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V]
2023     NIHR Health Technology Assessment programme One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023     National Institute for Health and Care Excellence (NICE) Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal). NICE technology appraisal guidance 923
2023     Haute Autorite de sante (HAS) [Transcutaneous ultrasound-guided intravenous radiofrequency occlusion of the small saphenous vein]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for ablation in cardiac arrhythmia]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third Addendum to Commission A21-130]
2023     NIHR Health Services and Delivery Research programme What factors are associated with informal carers’ psychological morbidity during end-of-life home care? A systematic review and thematic synthesis of observational quantitative studies
2023     National Institute for Health and Care Excellence (NICE) Tirzepatide for treating type 2 diabetes. NICE technology appraisal guidance 924
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2023     National Institute for Health and Care Excellence (NICE) Mirikizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 925
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2023     NIHR Health Services and Delivery Research programme Remote monitoring for long-term physical health conditions: an evidence and gap map
2023     National Institute for Health and Care Excellence (NICE) Baricitinib for treating severe alopecia areata. NICE technology appraisal guidance 926
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effects of treatment and social support measures in comorbidity]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Cost-effectiveness of newborn screening for tyrosinemia type I (update)]
2023     Agency for Care Effectiveness (ACE) Presbyopia-correcting intraocular lenses for treating patients with cataract
2023     National Institute for Health and Care Excellence (NICE) Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 927
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2023     Agency for Care Effectiveness (ACE) Minimally invasive glaucoma surgery (MIGS) implants for treating patients with mild to moderate primary open-angle glaucoma (POAG)
2023     National Institute for Health and Care Excellence (NICE) Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine. NICE technology appraisal guidance 928
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V]
2023     Agency for Care Effectiveness (ACE) SpaceOAR systems for rectum protection during prostate cancer treatment
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 929
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     WorkSafeBC Causal association between firefighting and hypersensitivity pneumonitis
2023     Agency for Care Effectiveness (ACE) Aortic hybrid stent graft for treating complex aortic disease
2023     National Institute for Health and Care Excellence (NICE) Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments. NICE technology appraisal guidance 930
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2023     WorkSafeBC Association between wearing orthosis and developing metatarsal stress fractures
2023     Agency for Care Effectiveness (ACE) Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2023     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 931
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023     WorkSafeBC Hemorrhoids and heavy lifting
2023     Agency for Care Effectiveness (ACE) Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2023     National Institute for Health and Care Excellence (NICE) Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 932
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023     WorkSafeBC HEPA filters and nanomaterials
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: evaluation and implementation of digital health solutions - a look at user participation]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     WorkSafeBC Firefighting and polycythemia vera
2023     National Institute for Health and Care Excellence (NICE) Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms. NICE technology appraisal guidance 934